X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) is being investigated as a combination for the treatment of late-stage pancreatic cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Details:
Ampligen (Rintatolimod) is an intraperitoneally administered small molecule drug candidate, which is currently being evaluated in combination with pembrolizumab and cisplatin for the treatment of recurrent ovarian cancer.
Lead Product(s): Rintatolimod,Pembrolizumab,Cisplatin
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2024
Details:
Ampligen (rintatolimod) is a TLR-3 agonist which is under phase 1/2 clinical development in combination with Imfinzi (durvalumab) for the treatment of pancreatic cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Ampligen (rintatolimod) is a TLR-3 agonist, small molecule drug candidate, which is being evaluated in phase 2 clinical trials for the treatment of Post-COVID conditions.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2024
Details:
Ampligen (rintatolimod) is a US-FDA approved TLR3 agonist. It is being evaluated in phase 2 clinical trials for the treatment of locally advanced pancreatic cancer.
Lead Product(s): Rintatolimod
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
Ampligen (rintatolimod) is a TLR-3 agonist which is being evaluated under phase 1/2 clinical trials in combination with anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) for the treatment of late-stage pancreatic cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
Ampligen (rintatolimod) is a TLR-3 agonist which is under phase 1/2 clinical development in combination with Imfinzi (durvalumab) for the treatment of pancreatic cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity, being developed as a potential therapeutic for people with the Post-COVID condition of fatigue.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity and is being evaluated in combination with Paclitaxel in Phase 1 Study for the treatment of people with early-stage triple negative breast cancer.
Lead Product(s): Rintatolimod,Celecoxib,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity and evaluating as a potential therapeutic for people with post-COVID conditions.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
